Literature DB >> 24413409

No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates.

Jennifer L Goldman1, Christopher J Harrison, Angela L Myers, Mary Anne Jackson, Rangaraj Selvarangan.   

Abstract

We evaluated vancomycin minimum inhibitory concentration (MIC) trends by 3 methods (broth microdilution, Etest and Vitek 2) in 208 Staphylococcus aureus blood isolates from 2006 to 2009 and assessed for heteroresistance. Vancomycin MICs did not increase nor was heteroresistance identified. Etest yielded higher MIC results than the other 2 methods. No MIC was >2 µg/mL by any testing method.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24413409      PMCID： PMC4608429          DOI： 10.1097/01.inf.0000436281.18687.0c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  9 in total

1.  Lack of increase in vancomycin resistance of pediatric methicillin-resistant Staphylococcus aureus Isolates from 2000 to 2007.

Authors:  Xiaotian Zheng; Chao Qi; Mollyn Arrieta; Amanda O'Leary; Deli Wang; Stanford T Shulman
Journal:  Pediatr Infect Dis J       Date:  2010-09       Impact factor: 2.129

2.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

3.  Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.

Authors:  Ravina Kullar; Susan L Davis; Donald P Levine; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

4.  Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.

Authors:  Edward O Mason; Linda B Lamberth; Wendy A Hammerman; Kristina G Hulten; James Versalovic; Sheldon L Kaplan
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

5.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

6.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

7.  Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.

Authors:  Steven N Leonard; Kerri L Rossi; Karly L Newton; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2009-01-09       Impact factor: 5.790

8.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

9.  Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States.

Authors:  Jeffrey S Gerber; Susan E Coffin; Sarah A Smathers; Theoklis E Zaoutis
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079
  9 in total
  8 in total

1.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

Review 2.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 3.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

4.  Association of Vancomycin MIC and Molecular Characteristics with Clinical Outcomes in Methicillin-Susceptible Staphylococcus aureus Acute Hematogenous Osteoarticular Infections in Children.

Authors:  Eric Y Kok; Jesus G Vallejo; Lauren M Sommer; Louie Rosas; Sheldon L Kaplan; Kristina G Hulten; J Chase McNeil
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Validation of a pediatric population pharmacokinetic model for vancomycin.

Authors:  Andrea Hahn; Robert W Frenck; Yuanshu Zou; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

6.  Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Authors:  Rana F Hamdy; Alice J Hsu; Chris Stockmann; Jared A Olson; Matthew Bryan; Adam L Hersh; Pranita D Tamma; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2017-05-05       Impact factor: 7.124

7.  Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome.

Authors:  J Chase McNeil; Eric Y Kok; Andrea R Forbes; Linda Lamberth; Kristina G Hulten; Jesus G Vallejo; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

8.  Decreased Vancomycin MICs among Methicillin-Resistant Staphylococcus aureus Clinical Isolates at a Chinese Tertiary Hospital over a 12-year Period.

Authors:  Chaohui Lu; Yinjuan Guo; Shanshan Wang; Zhengzheng Wang; Lan Chen; Jinnan Lv; Xiuqin Qi; Zengqiang Chen; Lizhong Han; Xueqing Zhang; Liangxing Wang; Fangyou Yu
Journal:  Front Microbiol       Date:  2016-10-27       Impact factor: 5.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.